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Abstract
Non-syndromic pituitary gigantism can result from AIP mutations or the recently identified Xq26.3 microduplication
causing X-linked acrogigantism (XLAG). Within Xq26.3, GPR101 is believed to be the causative gene, and the
c.924G > C (p.E308D) variant in this orphan G protein-coupled receptor has been suggested to play a role in the
pathogenesis of acromegaly.
We studied 153 patients (58 females and 95 males) with pituitary gigantism. AIP mutation-negative cases were
screened for GPR101 duplication through copy number variation droplet digital PCR and high-density aCGH. The
genetic, clinical and histopathological features of XLAG patients were studied in detail. 395 peripheral blood and 193
pituitary tumor DNA samples from acromegaly patients were tested for GPR101 variants.
We identified 12 patients (10 females and 2 males; 7.8 %) with XLAG. In one subject, the duplicated region only
contained GPR101, but not the other three genes in found to be duplicated in the previously reported patients, defining
a new smallest region of overlap of duplications. While females presented with germline mutations, the two male
patients harbored the mutation in a mosaic state. Nine patients had pituitary adenomas, while three had hyperplasia.
The comparison of the features of XLAG, AIP-positive and GPR101&AIP-negative patients revealed significant differences
in sex distribution, age at onset, height, prolactin co-secretion and histological features. The pathological features of
XLAG-related adenomas were remarkably similar. These tumors had a sinusoidal and lobular architecture. Sparsely and
densely granulated somatotrophs were admixed with lactotrophs; follicle-like structures and calcifications were
commonly observed. Patients with sporadic of familial acromegaly did not have an increased prevalence of the c.
924G > C (p.E308D) GPR101 variant compared to public databases.
In conclusion, XLAG can result from germline or somatic duplication of GPR101. Duplication of GPR101 alone
is sufficient for the development of XLAG, implicating it as the causative gene within the Xq26.3 region. The
pathological features of XLAG-associated pituitary adenomas are typical and, together with the clinical
phenotype, should prompt genetic testing.
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Introduction
X-linked acrogigantism (XLAG) is a recently identified
cause of early-onset pituitary gigantism [1, 2]. The
condition often manifests during the first year of life,
occurs more frequently in females usually as sporadic
disease with only two families reported so far [1]. XLAG
patients develop pituitary hyperplasia or mixed somato-
troph/lactotroph adenomas both resulting in significant
growth hormone (GH) excess [2]. All previously published
patients harbor Xq26.3 microduplications encompassing a
region of approximately 500Kb [1, 2]. This region contains
the locus of the GPR101 gene, encoding an orphan G
protein-coupled receptor (GPCR) that is significantly
overexpressed in the pituitary samples of XLAG patients.
In addition, the c.924G > C (p.E308D) GPR101 missense
variant was identified in 4.4 % of a series of patients with
sporadic acromegaly. This variant was suggested to
represent a disease-associated mutation, as it increases cell
proliferation and GH release in vitro [1].
The genetic background of non-syndromic gigantism
also includes inactivating germline mutations in the aryl
hydrocarbon receptor-interacting protein (AIP) gene.
These mutations are found in 29–50 % of gigantism
cases [3–5], causing a low-penetrance disease typically
manifesting clinically in the second decade of life, either
sporadically or in the setting of Familial Isolated Pituitary
Adenoma (FIPA).
In this study, we aimed to evaluate the prevalence of
Xq26.3 microduplication, a copy number variation
(CNV) gain including GPR101, in a large cohort of 153
patients with non-syndromic pituitary gigantism, who
were all screened for AIP mutations. We provide a de-
tailed clinical and histopathological description of this
condition and compare the clinical characteristics of gi-
gantism patients with GPR101, AIP and without
GPR101&AIP mutations. We also assessed the prevalence
of GPR101 variants in a large series of patients with
acromegaly.
Materials and methods
Patient selection
The study cohort consisted of 153 patients (58 females
and 95 males) diagnosed with pituitary gigantism. Patients
were recruited via the International FIPA consortium
network (http://www.fipapatients.org/fipaconsortium).
Pituitary gigantism was defined as GH excess associated
with accelerated growth velocity (> + 2 SDS, standard
deviation score) or abnormally tall stature (> + 3 SDS
above the normal mean height, i.e. Z-score > +3, or > +2
SDS above the mid-parental height) [3, 6]. Detailed clinical
and biochemical data were obtained from the referring
physicians. SDS for height and BMI were calculated based
on the Centers for Disease Control (CDC) growth charts
and, when available, by country-specific growth charts.
Other conditions predisposing to pituitary gigantism, in-
cluding McCune-Albright syndrome, Multiple Endocrine
Neoplasia type 1 (MEN1) and Carney complex, were ex-
cluded based on the clinical data and, when appropriate,
by genetic testing. Two patients from our cohort [7] were
previously reported to carry an Xq26.3 microduplication
[1, 2]. Additionally, the prevalence of GPR101 variants
was studied in a cohort of 579 acromegaly patients
(sporadic and familial) recruited through the FIPA
consortium. The study was approved by the local Ethical
Committee and informed consent was obtained from all
individual participants included in the study.
Genetic analyses
The AIP gene was tested in all patients through Sanger
sequencing and, in most patients, by MLPA dosage as
well, as previously described [7, 8]. Patients who were
not found to carry an AIP mutation were screened for
GPR101 duplication through CNV droplet digital PCR
(CNV ddPCR) for GPR101 in leukocyte- or saliva-
derived DNA and, in a subset of patients, in DNA
isolated from other sources (pituitary, palatine tonsil,
skin and buccal cells). When available, DNA samples
from both parents of identified XLAG patients were also
tested for GPR101 duplication using the CNV ddPCR.
Positive results were confirmed by means of standard and
high-density array comparative genomic hybridization
(HD-aCGH) and breakpoint junction analysis. Further
methodological details are shown in the Additional file 1.
Three hundred and ninety-five leukocyte- and 193
pituitary tumor-derived DNA samples from patients
with acromegaly (total number of patients = 579) were
tested for the c.924G > C (p.E308D) GPR101 variant
through Sanger sequencing. Leukocyte-derived DNA
samples were also tested for the previously reported
c.1098C > A (p.D366E) variant [9, 10]. Sanger sequencing
of the whole coding region of GPR101 was also
performed in a subset of DNA samples isolated from 42
randomly selected somatotroph adenomas. Primer
sequences are available upon request.
Pathological assessment
Pituitary adenoma tissue from six XLAG patients was
available for review and for further studies. Details of the
methods for immunohistochemistry, double immuno-
fluorescence and electron microscopy are reported in
the Additional file 1. Mitoses were counted in at least 30
fields at the magnification of x40 using a Nikon Eclipse
E600 microscope (Nikon UK, Kingston upon Thames,
UK) equipped with a Plan Fluor x40/0.75 objective.
Quantification of immunoreactions was performed on
images taken at the magnification of x20 with a Leica
DM5500 microscope (Leica, Wetzlar, Germany) coupled
with a Leica DFC295 camera (Leica). Scoring was
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performed independently by two co-authors (FR and
DI). Ki-67 labelling index was evaluated in at least five
representative areas counting at least 1000 cells; the
value was given as the percentage of positive nuclei.
Somatostatin receptor (SSTR) expression was scored as
previously described [11], taking into account the
localization and extent of the staining [12].
Statistical analysis
Parametric data are presented as mean ± standard
deviation (SD), and nonparametric data as median
[interquartile range, IQR]. Normal distribution was
assessed using the Shapiro-Wilk test. Data were analyzed
through univariate tests (Chi-square, ANOVA and
Kruskal-Wallis tests with Bonferroni and Dunn’s post-
hoc tests, as appropriate) using the software Prism v5
(GraphPad Software Inc, La Jolla, CA, USA). Signifi-
cance was set for P values <0.05.
Results
Genetics and family history
Of the 153 patients, 63 had AIP mutations (AIPpos,
41.2 %) (27 were sporadic and 36 familial) and 78
patients (GPR101&AIPneg, 51 %) were negative for both
AIP mutations and GPR101 duplication CNV. Twelve
patients (10 females, 2 males) with GPR101 duplication
were identified, accounting for 7.8 % of the whole cohort
and 17.2 % of females. The duplication appeared to be
germline in the ten female patients, while the two male
patients harbored the mutation in a mosaic state. In one
of these patients (case IX), the duplication was identified
by means of the CNV ddPCR in pituitary-, skin- and
palatine tonsil-derived but not in leukocyte-, saliva- or
buccal cell-derived DNA [13]. In the other case (case
VIII), the duplication was found in the pituitary tissue,
while saliva-derived DNA tested negative. Analysis of
leukocyte-derived DNA in this patient using the CNV
ddPCR showed intermediate results between normal and
duplicated dosage, suggesting the presence of a hetero-
geneous blood cell population as a result of somatic
mosaicism (Additional file 1: Figure S1).
The CNVs identified in subjects II, III, IV, V, VI, VII
and VIII encompassed four genes (CD40LG, ARHGEF6,
RBMX and GPR101) in the previously reported smallest
region of overlap [1]. Remarkably, the distal duplication
in case I narrowed down the smallest region of
overlap to a genomic region encompassing solely
GPR101 - the putative dosage-sensitive gene responsible
for the gigantism trait (Fig. 1). This patient’s duplication
was detected by GPR101 CNV ddPCR and HD-aCGH,
while it was not identified with standard aCGH. While
most patients’ duplications occurred as a result of the
fork stalling and template switching/microhomology-
mediated break-induced replication (FoSTeS/MMBIR)
mechanism, in one patient (case III) the duplication was
generated via an Alu-Alu mediated rearrangement
(Additional file 1: Table S1). There was no history of
pituitary disease in any of these patients’ families. The
duplication was found to have occurred de novo in each
of the germline mutation cases where DNA samples
were available from both parents (4/10 patients).
Clinical and biochemical features
XLAG patients were generally born at full term and had
normal birth length and weight. One patient (case IX)
was born large for gestational age (+2.4 SDS). All
patients presented with accelerated growth starting as
early as seven months of age with a median age at onset
of 1.9 years [1.1–2.4]. The median age at diagnosis of
gigantism was 4.4 years [2.7–6.7]. Median delay between
onset of the disease and diagnosis was 2.6 years [1–3.7].
The median height SDS was +5.4 [4–6.3]. BMI SDS was
increased in four out of seven patients with available
data, with a median of +2.2 [1.2–3]. Details of symptoms
at presentation are shown in the Additional file 1.
Basal GH levels were increased in all patients. IGF-1
levels were increased at 2.9xULN (upper limit of normal)
[2–3.9]. Oral glucose tolerance test showed unsup-
pressed GH (available for 8/12 patients) with a mean
change in GH levels of −14.5 % ± 25.5; two patients pre-
sented a paradoxical increase of GH levels in response
to the glucose load. Patient IV showed a paradoxical rise
of GH after thyrotropin-releasing hormone (TRH), and
an increase of both GH and prolactin (PRL) levels after
the administration of growth hormone-releasing hor-
mone (GHRH) [14]. PRL was elevated in ten patients
with a median of 6.9xULN [3.3–11.3]. Circulating
GHRH was measured in the three patients with pituitary
hyperplasia and was within the reference range. None of
the other pituitary axes was affected at diagnosis in any
of the patients. No differences in clinical and biochem-
ical parameters were evident between patients carrying
germline or somatic GPR101 duplication.
Tumor size and extension
Nine of the 12 XLAG patients (75 %) had macroadeno-
mas. Median maximum tumor size was 18 mm [14–25.5].
All the adenomas showed suprasellar extension, and three
lesions extended into the cavernous sinus. MRI of three
patients (patient II, IV and IX) (25 % of our XLAG cases)
showed diffuse enlargement of the gland suggestive of
pituitary hyperplasia rather than a distinct adenoma.
Representative MRI images are shown in the Additional
file 1: Figure S2.
Histological and immunohistochemical features
The features of the XLAG-related pituitary adenomas
were remarkably similar. They were characterized by a
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predominantly sinusoidal, lobular and acinar rather than
diffuse architecture (Fig. 2a, b). The network of reticulin
fibers was disrupted in all tumors although reticulin
fibers were still evident in the perivascular connective
which appeared stretched and distorted (Fig. 2c, d).
Areas of acidophilic cells were admixed with distinct
areas of chromophobic cells. Acidophilic cells had large,
intensely eosinophilic cytoplasm and centrally placed,
rounded nucleus with coarse chromatin and single
eosinophilic nucleolus. None of the adenomas investi-
gated in our study contained obvious areas of hyperpla-
sia. Pseudo-follicles containing colloid-like material were
noted (Fig. 3a). There was some degree of nuclear
pleomorphism (Fig. 3b). Microcalcifications (Fig. 3c) and
sparse psammomatous bodies were a frequent feature.
Mitotic activity was generally low with an average of one
mitosis per 30 high-power fields. None of the adenomas
showed necrosis or hemorrhagic changes. One case was
adjacent to a Rathke’s cleft cyst.
On immunohistochemistry, the predominant acidophilic
component showed intense positivity for GH, in keeping
with densely granulated (DG) somatotrophs (Fig. 4a).
Chromophobic cells were less numerous than acidophilic
cells accounting for up to approximately 25 % of the
whole tumor. The chromophobic component consisted of
two cell types. The commonest cells showed large, faintly
stained cytoplasm and central nucleus with fine chromatin
and inconspicuous nucleolus. These chromophobic cells
showed paranuclear positivity for PRL, in keeping with
sparsely granulated (SG) lactotrophs (Fig. 4b). Less nu-
merous and mostly interspersed between the acidophilic
cells, were slightly smaller chromophobic cells with
eccentric nucleus, some of which contained discernible fi-
brous bodies. These SG somatotroph cells showed weak
GH expression (Fig. 5a); fibrous bodies were positive for
cytokeratin CAM5.2 (Fig. 5b). One patient (case VIII) had
transsphenoidal surgery following radiotherapy. His tumor
retained the same features of the other adenomas but it
showed more hyperchromatic nuclei and perivascular
fibrosis (Additional file 1: Figure S3A). A few mitoses, one
of which was atypical, were also present in this case
(Additional file 1: Figure S3B).
(See figure on previous page.)
Fig. 1 Genomic rearrangements identified in eight subjects with duplications encompassing GPR101. The HD-aCGH log2 ratio plot for each rearrangement
is aligned within the genomic interval of ChrX: 135379766–136479766 (x axis), with the identification of each subject on the y axis. The
cluster of red dots shows interrogating oligonucleotide probes that demonstrate increased hybridization intensity, revealing a gain in copy number.
The gene content included in the duplicated region is shown underneath the aligned HD-aCGH log2 ratio plots. The symbols on the right side of the
gene names represent the structure of the genes, with vertical lines representing exons. GPR101, a single exon gene, is highlighted in red. The region
between the black vertical lines across the log2 ratio plots and gene track represent the smallest region of overlap encompassing solely GPR101, but
not the other three genes (CD40LG, ARHGEF6 and RBMX) in the smallest region of overlap of previously published patients. Red probes, log2 ratio >
0.25; black probes, −0.25≤ log2 ratio≤ 0.25; green probes, log2 ratio < −0.25
Fig. 2 Adenomas occurring in XLAG patients are characterized by distinct populations of acidophilic and chromophobic cells (a HE - x10; b HE x40);
staining for reticulin fibers highlights the lobular and cordonal architecture of XLAG-related adenomas (c Gordon-Sweet’s silver impregnation - x10);
perivascular connective tissue containing thickened and distorted reticulin fibers (d Gordon-Sweet’s silver impregnation – x40)
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Scattered adenoma cells showed expression of the
common α-subunit (Fig. 4c), while the immunoreactions
for ACTH and FSH, LH and TSH β-subunits were
negative. Double immunofluorescence highlighted two
distinct populations of GH- and PRL-positive cells and
no co-localization of the two hormones (Fig. 4d). The
transcription factor PIT-1 was expressed in over 90 % of
tumor cells (Fig. 5c). The Ki-67 labelling index was
lower than 3 % in all cases (Fig. 5d). Weak nuclear p53
expression was noted in all XLAG adenomas, and the
degree of expression was similar to sporadic somato-
troph adenomas tested as controls. SSTR2a and SSTR5
expression was variable and both cytoplasmic and
membranous (scores 1 and 2), although none of the
adenomas reached score 3 indicating circumferential
membranous staining in more than 50 % of tumor cells.
AIP expression was moderate to strong while GHRH
immunostaining was negative in all cases. Histological
examination of the previously published cases of
hyperplasia (case IV and IX) revealed similar features, in-
cluding enlarged acini with preservation of the reticulin
network, substantial increase in somatotroph and
lactotroph cells, and scattered cells expressing ACTH
and FSH, LH and TSH β-subunits [13, 14].
Fig. 3 Secondary features of XLAG adenomas include pseudo-follicles containing colloid-like material (asterisk) (a HE – x20), isolated cells with
large, irregular nucleus (b HE – x20), and scattered calcifications (arrow) (c HE – x20)
Fig. 4 DG somatotrophs represent the predominant component in XLAG adenomas (a GH staining with immunoperoxidase – x10),
while neoplastic lactotrophs appear as smaller areas (b PRL staining, immunoperoxidase – x10); some tumor cells express the common
α-subunit (c immunoperoxidase – x20); double immunofluorescence for GH (green) and PRL (red) shows lack of co-localization of the
two hormones in neoplastic cells (d immunofluorescence – x63)
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Electron microscopy
On electron microscopy, the main cell population in
XLAG adenomas was represented by DG cells with well-
developed Golgi complexes and rough endoplasmic
reticulum containing granules ranging between 250-
600 nm in size resembling DG somatotroph cells. Most
of the SG cells resembled lactotrophs, showing periph-
eral granules measuring between 150 and 300 nm and
abundant endoplasmic reticulum, while scattered SG
somatotroph cells containing fibrous bodies and
granules between 200 and 450 nm were also identified
(Figure S4). In the hyperplasia cases, a non-tumoral
adenohypophysis was seen, dominated by cells with
ultrastructural features of somatotrophs and lactotrophs.
Many cells containing large pleomorphic secretory
granules and exocytosis were identified, showing co-
localization of GH and PRL within the same cell and the
same granules, as assessed by immunoelectron micros-
copy in case IV [14], in keeping with mammosomato-
troph cells.
Treatment and outcomes
The clinical features, treatment and outcomes of XLAG
patients are detailed in the Additional file 1: Table S2.
The median number of treatments per patient was 3.5
[2–4.7]. Five patients received medical therapy as first-
line treatment, either with somatostatin analogues
(SSAs) combined with dopamine agonists (DAs) (four
patients) or DAs alone (one patient), with overall poor
results. The GH receptor antagonist pegvisomant was
effective in normalizing IGF-1 levels and growth velocity
in three of the four patients in whom it was used.
Overall, eight out of the 11 patients with surgical or
radiotherapeutical intervention developed partial or
complete hypopituitarism. Median duration of follow-up
was 10.6 years [4.4–22.9]. At the last follow up, overall
disease control had been achieved in 11/12 patients,
including remission (n = 4), disease control (normal age-
adjusted IGF-1 in patients on pegvisomant, n = 3) and
partial control (normal age-adjusted IGF-1 and random
GH >1 ng/ml in patients on SSAs and/or DAs, n = 4).
No other tumors were found to date; the oldest
patient with GPR101 duplication in our series is now
50 years old and has not developed any other disease
manifestation.
Comparison of clinical characteristics of XLAG, AIPpos and
GPR101&AIPneg patients
Sex distribution, clinical and biochemical parameters,
and MRI findings observed in XLAG patients were
compared to those of AIPpos and GPR101&AIPneg pa-
tients (Additional file 1: Table S3). Ten of the 12 XLAG
patients were females, as opposed to 31.7 % of AIPpos
and 35.9 % of GPR101&AIPneg cases (P < 0.001 for both
comparisons). The median age at onset and diagnosis in
XLAG patients was significantly earlier compared to
AIPpos and GPR101&AIPneg patients (P < 0.001 for both
comparisons). The height SDS was also significant
higher in XLAG patients compared to GPR101&AIPneg
(P < 0.01) and AIPpos cases (P < 0.05).
No significant difference was found in IGF-1 levels at
diagnosis. Hyperprolactinemia was significantly more
Fig. 5 Immunostaining demonstrates areas composed of cells with faint GH expression containing fibrous bodies (arrow) (a immunoperoxidase – x20;
insert – x40). Fibrous bodies are positive for cytokeratin CAM5.2 (b immunoperoxidase – x20); the transcription factor PIT-1 is expressed in the majority
of the cells (c immunoperoxidase – x20); the Ki-67 labelling index is <3 % in all cases (d immunoperoxidase – x20)
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prevalent in XLAG (83.3 %), compared to AIPpos (23.5 %,
P < 0.001) and GPR101&AIPneg patients (32.3 %, P < 0.01).
Median maximum tumor diameter and proportion of
macroadenomas was not significantly different in the three
groups, although no giant adenomas were found in XLAG
patients, while they represented 25–30 % of the cases in
the other two groups (P < 0.05 XLAG vs GPR101&AIPneg).
Pituitary hyperplasia was significantly more common
in XLAG patients (25 %), compared to AIPpos (2.6 %,
P < 0.05) and GPR101&AIPneg cases (none, P < 0.01). No
difference was found in the rate of suprasellar exten-
sion and cavernous sinus invasion. Pituitary apoplexy
was not observed in XLAG patients, while it occurred
in 14.5 % of AIPpos and 2.9 % of GPR101&AIPneg
cases. There was no significant difference in the rate
of hypopituitarism and number of treatments.
GPR101 variants in acromegaly patients
We sequenced DNA samples from 579 acromegaly pa-
tients (395 leukocyte- and 193 pituitary tumor-derived)
and identified four patients (0.69 %) harboring the germ-
line GPR101 c.924G > C (p.E308D) variant. None of
these patients had a family history of pituitary adenoma.
The allele frequency of the c.924G > C (p.E308D) variant
in our series (0.45 %) was similar to that reported in the
Exome Aggregation Consortium Database (ExAC)
(0.37 %, P = 0.69). The c.1098C > A (p.D366E) variant
was not identified in any of the 395 leukocyte-derived
DNA samples. The full coding region of the GPR101 gene
was sequenced in 42 unselected sporadic somatotroph
adenomas. Two common single nucleotide variants were
identified: c.370G > T (p.V124L) (rs1190736, minor allele
frequency ExAC database 38 %) and c.1127 T > C
(p.L376P) (rs5931046, minor allele frequency 17.2 %). No
rare or novel variants were found.
Discussion
In this large international cohort of patients with non-
syndromic pituitary gigantism, we identified germline or
somatic GPR101 duplication causing XLAG in 8 % of
patients. This frequency, consistent with previously
published findings [5], supports the need for testing for
GPR101 duplication in patients with early-onset pituitary
gigantism.
Our results provide significant and clinically relevant
mechanistic insights on XLAG. Firstly, we provide proof
that duplication of GPR101 is sufficient to cause the
XLAG phenotype. HD-aCGH in one of the patients
from our series has allowed the definition of a new
smallest region of overlap in XLAG patients to an area
encompassing GPR101 only, but not the other three
genes (CD40LG, ARHGEF6 and RBMX) previously
identified in the duplicated region [1, 2, 15, 16].
Furthermore, our results indicate that, as such small
duplications cannot be found on a standard aCGH array,
alternative diagnostic methods should be employed, such
as CNV ddPCR for GPR101 or HD-aCGH.
Secondly, as recently described [13, 16], XLAG can
result from a duplication occurring during an early
postzygotic stage, resulting in somatic mosaicism. The
only two male subjects in our series were mosaic for the
GPR101 duplication. In one of these patients, the CNV
ddPCR did not show the presence of the duplication in
leukocyte-derived DNA [13], indicating that, in the
presence of a clinical phenotype suggestive of XLAG,
analysis of pituitary- or other tissues-derived DNA
samples should be considered in order to confirm the
diagnosis.
Thirdly, we have described in detail the histopatho-
logical features of XLAG adenomas. Most XLAG pa-
tients develop mixed somatotroph/lactotroph adenomas
that show a characteristic sinusodoidal and lobular
architecture and contain both DG and SG somatotroph
cells. Microcalcifications and follicle-like structures are
commonly observed. Mitotic activity was negligible in
five of our cases and the Ki-67 labelling index never
exceeded 3 %.
Adenomas observed in patients with XLAG differ
from other GH-secreting adenomas. The classification of
somatotroph adenomas is based on morphological,
ultrastructural and immunophenotypical features, and
includes the common DG and SG somatotroph
adenomas, mixed somatotroph/lactotroph adenomas
[17], as well as the less frequent mammmosomatotroph
[17], silent type III [18] and acidophilic stem cell
adenomas [19]. Neoplastic cells of DG somatotroph
adenomas typically show acidophilic cytoplasm with
intense and widespread immunoreactivity for GH. At
electron microscopy, cells resemble normal somatotrophs.
Other anterior pituitary hormones are often expressed,
including PRL, the common α-subunit and β-subunits of
FSH, LH and TSH in various combinations. Prolactin
immunoreactivity is by far the commonest in DG
adenomas and, in fact, about 50 % of acromegaly patients
present with signs and symptoms of hyperprolactinemia
[20]. SG somatotroph adenomas are composed of smaller
cells, have chromophobic cytoplasm with faint and focal
immunoreactivity for GH, reflecting the paucity of
secretory granules seen at electron microscopy. SG aden-
omas contain distinctive paranuclear cytokeratin-positive
inclusions known as fibrous bodies. Immunoreactivity for
other pituitary hormones is considerably less common
than DG adenomas and, when present, their expression is
weak. In about 25 % of somatotroph adenomas, tumor
cells show intermediate features between DG and SG cells
[21], a feature we did not observe in XLAG. In mixed
somatotroph/lactotroph adenomas, the degree of hor-
mone expression and distribution of GH and PRL-positive
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cells vary among cases. Mixed adenomas contain either
DG or SG somatotrophs admixed with lactotroph cells
[17, 22]; the coexistence of DG and SG somatotroph cells
observed in XLAG-related adenomas has never been
formally described to the best of our knowledge.
The distinction between nodular hyperplasia and ad-
enoma is certainly challenging, given the lobular, acinar
and sinusoidal/cordonal architecture of XLAG-related
adenomas. Several features are, however, in keeping with
a neoplastic rather than a hyperplastic process. Firstly,
reticulin fibers are almost exclusively limited to perivas-
cular spaces, which appeared thickened, distorted and
stretched. Secondly, we are not aware of any description
of somatotroph hyperplasia containing SG somatotroph
cells [23, 24]. In addition, proliferative activity identified
with Ki-67, and the presence of a few mitoses, are
further features indicative of an adenoma rather than
hyperplasia.
It is important to consider that GH excess was caused
by mammosomatroph hyperplasia in two of our XLAG
patients [13, 14], while one hyperplasia patient had pure
GH excess (case II). Interestingly, none of the adenomas
examined in this study demonstrated a transition from
hyperplasia to adenoma or showed any tumor cells with
GH and PRL co-localization. Sampling may explain the
lack of hyperplasia, although we cannot exclude that
mammosomatotroph hyperplasia and mixed somato-
troph/lactotroph adenomas represent distinct pathological
manifestations of XLAG.
The mechanisms underlying the molecular pathogen-
esis of XLAG are unknown. GPR101 encodes an orphan
GPCR [25]. In mice, GPR101 is expressed throughout
the central nervous system, with higher levels observed
in the hypothalamus [1, 25]. The finding of increased
circulating GHRH levels in some patients with XLAG
[1, 2, 26] and in other cases with a phenotype highly
suggestive of XLAG [27, 28], suggests that upregulation
of hypothalamic GHRH might play a pathogenic role. Not-
ably, adenomatous transformation to a SG somatotroph
adenoma was reported in a case of pituitary hyperplasia
and ectopic acromegaly due to a pituitary metastasis from
a GHRH-secreting neuroendocrine tumor [29]. Mammo-
somatotroph cells account for a sizeable proportion of the
human fetal anterior pituitary and are considered precur-
sors of GH and PRL cells in the adult anterior pituitary
[30, 31]. These bi-hormonal cells are frequently found in
gigantism [32], while they are rare in adult acromegaly
patients [20]. The expansion of mammosomatotrophs
observed in XLAG patients with pituitary hyperplasia
could potentially result from prenatal exposure to in-
creased GHRH levels. Interestingly, mice transgenic for
GHRH develop mammosomatotroph hyperplasia [33], and
occurrence of somatotroph adenomas has been described
in older animals [34]. Moreover, the pituitary cells from
one of our patients were found to normally respond to
octreotide and bromocriptine treatment in vitro, despite
only a marginal biochemical response in vivo [14], further
supporting the role for a stimulatory factor hampering re-
sponsiveness to medical treatment. Duplication of GPR101
might potentially affect the GH axis both at the pituitary
and the hypothalamic level. In fact, GPR101 is coupled to
the stimulatory G protein [25] and, in GH3 mammosoma-
totroph cells, overexpression of GPR101 has been found to
increase cAMP levels [1], which represents a key factor
involved in the regulation of GH secretion and cell prolifer-
ation in response to GHRH [35, 36].
Patients with XLAG have a unique clinical phenotype,
whether it is a result of a germline or somatic GPR101
duplication. The disease presents very early; excessive
growth started before four years of age and was the
presenting feature in all patients. We confirmed that
XLAG is more common in females, occurs earlier and is
more frequently associated with hyperprolactinemia,
compared with gigantism due to AIP mutations. Pituit-
ary adenomas in AIP mutation carriers are frequently
large and invasive, invariably SG and often characterized
by a high proliferation index [3, 5, 37]. Considering the
marginal overlap we observed between XLAG and AIP-
pos patients in regards to the age at disease onset, in the
rare case of young-onset gigantism due to an AIP muta-
tion [38], neuroimaging and pathological features can
help in the differential diagnosis. Interestingly, two of
our youngest AIPpos cases (aged 4 and 6) presented with
pituitary apoplexy [8, 38], which was not observed
among XLAG patients. Moreover, although described in
the setting of AIP-related pituitary disease [39], hyper-
plasia is an unusual finding in AIPpos cases, occurring
only in one patient in our series [3].
XLAG patients frequently require multi-modal treat-
ment. First generation SSAs are usually ineffective, while
dopamine agonists effectively control PRL excess in the
cases where appropriate doses are used, although they
don’t seem to have a significant effect on GH and IGF-1
levels. A combination of surgery and radiation was
necessary in most patients, and, in some of them,
allowed the control of GH excess with further use of
SSAs. Pegvisomant was an effective treatment both (i) in
patients whose disease was not controlled despite multi-
modal treatment, and (ii) in patients with pituitary
hyperplasia, where extensive pituitary surgery was not
considered due to the risk of hypopituitarism.
Finally, we investigated the prevalence of GPR101
variants in a large series of acromegaly patients. The
frequency of the previously reported c.924G > C
(p.E308D) variant in our cohort was found to be similar
to that reported in the ExAC database. No other rare or
novel coding variants were identified, either at the germ-
line or somatic level, suggesting that GPR101 variants do
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not occur frequently and might not play a significant
role in the pathogenesis of acromegaly. These results are
in line with recently published studies [10, 40].
Conclusion
XLAG accounts for a significant proportion of patients
with non-syndromic gigantism, and results from either
germline or somatic duplications involving GPR101, which
we have proved to be the causative gene within the Xq26.3
region. Our data suggest that specific testing for GPR101
duplication and, in some cases, testing of alternative tissue-
derived DNA samples, should be employed for the genetic
diagnosis of XLAG. Most XLAG patients develop pituitary
adenomas showing remarkably similar histopathological
features, including sinusoidal and lobular architecture, the
presence of both DG and SG somatotrophs admixed with
lactotroph cells, follicle-like structures and calcifications.
These features, together with the clinical phenotype,
should raise the suspicion of XLAG. Further studies are
needed to untangle the molecular mechanisms involved in
the pathogenesis of this condition.
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